查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1763206

全球止血诊断市场

Hemostasis Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 173 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球止血诊断市场规模将达到 32 亿美元

全球止血诊断市场规模预计在2024年为24亿美元，预计到2030年将达到32亿美元，在2024-2030年的分析期间内，复合年增长率为4.8%。报告分析的细分市场之一——凝血酶原检测时间(PT)——预计其复合年增长率为4.6%，到分析期结束时规模将达到13亿美元。 D-二聚体细分市场在分析期间的复合年增长率预计为5.7%。

美国市场规模估计为 6.367 亿美元，中国市场预计复合年增长率为 8.4%

美国止血诊断市场规模预计在2024年达到6.367亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到7.363亿美元，在2024-2030年的分析期间内，复合年增长率为8.4%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为1.7%和4.8%。在欧洲，预计德国市场的复合年增长率为2.2%。

全球止血诊断市场－主要趋势与驱动因素摘要

止血诊断在患者照护中扮演什么角色？

止血诊断对于评估血友病、深层静脉栓塞症和血管性血友病等凝血障碍至关重要。这些诊断可以测量各种凝血因子、血小板功能和凝血时间，为出血性疾病的管理和血栓事件的预防提供宝贵资讯。止血检测对于术前评估和抗凝血治疗的监测也至关重要，准确及时的结果对于病人安全至关重要。出血性疾病正变得越来越普遍，尤其是在人口老化的情况下，这使得止血诊断在常规诊疗和急诊中都变得越来越重要。

为什么止血诊断技术的进步很重要？

技术进步正在提高止血诊断的准确性和效率。自动凝血分析仪和黏弹性测试等创新技术能够实现更快、更详细的评估，这对于管理出血风险至关重要。照护现场设备也越来越普及，使医护人员能够在门诊进行止血测试并即时获得结果。这些进步正在提高诊断的速度和准确性，有助于改善患者预后并监测治疗效果，尤其是在严重情况下。

医疗保健法规如何影响止血检测？

医疗保健法规在止血诊断中发挥关键作用，因为准确可靠的检测对病人安全至关重要。监管机构对诊断设备和试剂施加了严格的品质标准，以确保检测的可靠性。这些标准是强制性的，鼓励医疗保健提供者投资符合监管要求的先进诊断设备。这种对合规性的关注推动了对经过认证的高品质止血诊断设备的需求，以确保患者照护的安全有效。

是什么推动了止血诊断市场的成长？

出血性疾病管理需求的不断增长、诊断设备的技术进步以及严格的医疗法规推动了止血诊断市场的成长。随着出血性疾病盛行率的上升，对准确及时诊断的需求也日益增长。技术创新提高了诊断的准确性和效率，使这些检测对于患者安全和有效治疗至关重要。监管标准对高品质诊断的要求进一步推动了市场成长，使止血诊断成为患者照护的重要组成部分。

部分

检验类型（凝血酶原时间 (PT)、D-二聚体、纤维蛋白原、活化部份凝血活酵素时间）、最终使用者（医院、诊断中心、其他最终使用者）

受访公司范例

  • Abbott Laboratories
  • Alere, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Instrumentation Laboratory
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

人工智慧集成

我们正在利用可操作的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP16458

Global Hemostasis Diagnostics Market to Reach US$3.2 Billion by 2030

The global market for Hemostasis Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Prothrombin Test Time (PT), one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the D Dimer segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$636.7 Million While China is Forecast to Grow at 8.4% CAGR

The Hemostasis Diagnostics market in the U.S. is estimated at US$636.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$736.3 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Hemostasis Diagnostics Market - Key Trends & Drivers Summarized

What Role Do Hemostasis Diagnostics Play in Patient Care?

Hemostasis diagnostics are crucial for assessing blood clotting disorders, such as hemophilia, deep vein thrombosis, and von Willebrand disease. These diagnostics measure various clotting factors, platelet function, and coagulation time, providing valuable information for managing bleeding disorders and preventing thrombotic events. Hemostasis testing is also essential for pre-surgical assessments and monitoring anticoagulant therapy, where accurate and timely results are critical for patient safety. As bleeding disorders become more prevalent, particularly with aging populations, hemostasis diagnostics are increasingly important in both routine care and emergency settings.

Why Are Technological Advancements in Hemostasis Diagnostics Important?

Technological advancements are enhancing the accuracy and efficiency of hemostasis diagnostics. Innovations like automated coagulation analyzers and viscoelastic testing are enabling faster, more detailed assessments, which are crucial in managing bleeding risks. Point-of-care devices are also gaining popularity, allowing healthcare providers to perform hemostasis tests in outpatient settings and receive results in real time. These advancements help improve diagnostic speed and accuracy, supporting better patient outcomes and treatment monitoring, particularly in critical care situations.

How Are Healthcare Regulations Impacting Hemostasis Testing?

Healthcare regulations play a significant role in hemostasis diagnostics, as accurate and reliable testing is essential for patient safety. Regulatory agencies enforce strict quality standards for diagnostic instruments and reagents to ensure test reliability. Compliance with these standards is mandatory, prompting healthcare providers to invest in advanced diagnostic equipment that meets regulatory requirements. This focus on regulatory compliance is driving demand for certified, high-quality hemostasis diagnostics, ensuring safe and effective patient care.

What Drives the Growth of the Hemostasis Diagnostics Market?

The growth in the hemostasis diagnostics market is driven by increased demand for bleeding disorder management, technological advancements in diagnostic devices, and strict healthcare regulations. As the prevalence of bleeding disorders rises, there is growing demand for accurate and timely diagnostics. Technological innovations are enhancing diagnostic precision and efficiency, making these tests essential for patient safety and effective treatment. Regulatory standards that mandate high-quality diagnostics are further supporting market growth, positioning hemostasis diagnostics as a critical component of patient care.

SCOPE OF STUDY:

The report analyzes the Hemostasis Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Prothrombin Test Time (PT), D Dimer, Fibrinogen, Activated Partial Thromboplastin Time); End-Use (Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • Alere, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Instrumentation Laboratory
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Hemostasis Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Hemostasis Testing in Surgical and Critical Care
    • Growth in Point-of-Care Hemostasis Testing Solutions for Rapid Results
    • Advancements in Coagulation Analyzers for Enhanced Precision
    • Expansion of Hemostasis Diagnostics in Hemophilia and Thrombosis
    • Higher Demand for Personalized Hemostasis Testing Solutions
    • Development of Automated Hemostasis Analyzers in Clinical Labs
    • Growth in Demand for Anti-Coagulation Monitoring Solutions
    • Increased Adoption of AI-Driven Hemostasis Data Analytics
    • Expansion of Testing in Pre-Surgical and Critical Care Settings
    • Rising Use of Hemostasis Diagnostics in Blood Disorder Management
    • Growth of Home Testing Options for Hemostasis Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Hemostasis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Prothrombin Test Time (PT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for D Dimer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Activated Partial Thromboplastin Time by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • JAPAN
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • CHINA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • EUROPE
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • FRANCE
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • GERMANY
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • INDIA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hemostasis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hemostasis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • AFRICA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030

IV. COMPETITION